Abstract: The continuous identification of molecular changes deregulating critical pathways in pancreatic tumor cells provides us with a large number of novel candidates to engineer gene-targeted approaches for pancreatic cancer treatment. Targets—both protein coding and non-coding—are being exploited in gene therapy to influence the deregulated pathways to facilitate cytotoxicity, enhance the immune response or sensitize to current treatments. Delivery vehicles based on viral or non-viral systems as well as cellular vectors with tumor homing characteristics are a critical part of the design of gene therapy strategies. The different behavior of tumoral versus non-tumoral cells inspires vector engineering with the generation of tumor selective products that can prevent potential toxic-associated effects. In the current review, a detailed analysis of the different targets, the delivery vectors, the preclinical approaches and a descriptive update on the conducted clinical trials are presented. Moreover, future possibilities in pancreatic cancer treatment by gene therapy strategies are discussed.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Fillat, C.; Jose, A.; Bofill-De Ros, X.; Mato-Berciano, A.; Maliandi, M.V.; Sobrevals, L. Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems. Cancers 2011, 3, 368-395.
Fillat C, Jose A, Bofill-De Ros X, Mato-Berciano A, Maliandi MV, Sobrevals L. Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems. Cancers. 2011; 3(1):368-395.
Fillat, Cristina; Jose, Anabel; Bofill-De Ros, Xavier; Mato-Berciano, Ana; Maliandi, Maria Victoria; Sobrevals, Luciano. 2011. "Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems." Cancers 3, no. 1: 368-395.